PledPharma’s drug candidate Aladote® is highlighted at one of the largest liver conferences globally
April 12, 2019
Stockholm, April 12, 2019. Today, the Aladote® proof of principle study will be presented at the global scientific conference EASL ILC. EASL ILC has chosen to recognise the study results as one of today’s highlights at the conference with a press release to media and the international scientific community.
EASL ILC, also known as The International Liver Congress, is one of the largest scientific conferences in the field of Hepatology (liver diseases) globally. The conference takes place in Vienna, Austria, April 10-14. Dr James Dear will present the results together with PledPharma’s CMO, Dr. Stefan Carlsson. Dr Dear, an internationally leading paracetamol toxicity expert, was the Principal Investigator for the Proof of Principle Phase Ib/IIa study, conducted at the Royal Infirmary of Edinburgh and the Queen’s Medical Research Institute, University of Edinburgh. Time, date and session location at the conference: 16:30–16:45, 12 April 2019, Lehar 4.
“It is very gratifying that EASL (The European Association for the Study of the Liver) has chosen to highlight our Aladote® POP-study and its results in this extraordinary way. We see this as yet another confirmation that Aladote® results generate great interest to potentially meet the unmet medical need for the treatment of paracetamol poisoning beyond current standard of care,” says Nicklas Westerholm, CEO PledPharma.
Link to the press release from EASL: https://ilc-congress.eu/press-release/calmangafodipir-may-reduce-liver-injury-after-paracetamol-overdose-final-results-from-the-pop-trial/
Link to the live webcast: https://easl.meta-dcr.com/ilc2019/channels
For further information, please contact:
Yilmaz Mahshid, CFO
Ph. +46 (0)72 231 68 00
[email protected]
About PledPharma
PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company’s most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A global phase III program is ongoing. The drug candidate Aladote® is being developed to reduce the risk of acute liver injury associated with acetaminophen poisoning. A proof of principle study has been successfully completed and will serve as the basis for the continued development. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 83 00, [email protected]). For more information, see http://www.pledpharma.com/
Aladote®
Aladote® is a “first-in-class” drug candidate with the potential to prevent the development of acute liver failure caused by paracetamol overdose. Aladote® has shown good efficacy in relevant preclinical models, even in the time-window when N-acetylcysteine (NAC) treatment is no longer is effective. A proof of principle study in patients with paracetamol poisoning has been successfully completed. Aladote® has been granted Orphan Drug Designation in the US.
Paracetamol is the most used drug in the world for the treatment of fever and pain, but also one of the most overdosed drugs – intentional or unintentional. Paracetamol overdose is also one of the most common method in intentional suicide attempts. When excessive amounts of paracetamol are broken down in the liver, the harmful metabolite NAPQI is formed, which can cause acute liver failure. The current standard of care for paracetamol poisoning (NAC) is effective if the patient seeks medical care within 8 hours of ingestion. However, NAC is substantially less effective if started more than 8 hours after overdose.
